Amgen (AMGN)
(Delayed Data from NSDQ)
$305.85 USD
+4.85 (1.61%)
Updated May 31, 2024 04:00 PM ET
After-Market: $305.50 -0.35 (-0.11%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$305.85 USD
+4.85 (1.61%)
Updated May 31, 2024 04:00 PM ET
After-Market: $305.50 -0.35 (-0.11%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is First Trust Dow 30 Equal Weight ETF (EDOW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EDOW
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPYD
Should First Trust Dow 30 Equal Weight ETF (EDOW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EDOW
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Company News for Nov 01, 2023
by Zacks Equity Research
Companies In The Article Are: AMGN, NVDA, RGEN, COCO
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View
by Zacks Equity Research
Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.
Here's What Key Metrics Tell Us About Amgen (AMGN) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amgen (AMGN) Q3 Earnings Top Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 6.67% and 0.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY
by Zacks Equity Research
Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.
Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View
by Zacks Equity Research
AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.